Cloxacillin
- Exhibits good activity against Staphylococcus aureus
- has activity against many streptococci but is less active than penicillin and is generally not used in clinical practice to treat streptococcal infections
Unasyn
- Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria
Comparison : Staphylococcus Aureus
Coverage
- Unasyn covers for both S. aureus (beta-lactamase and non-beta-lactamase producing)
- Staphylococcal beta-lactamase is readily inhibited by the currently available beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam. Thus, combination of these inhibitors with beta-lactamase-labile penicillins restores activity against penicillin-resistant, methicillin-susceptible staphylococci
- Staphylococci resistant to methicillin, oxacillin, or nafcillin must be considered resistant to Unasyn.
- When additional strains were used in the model, oxacillin and ampicillin-sulbactam (1,000 plus 2,000 mg/kg/day) were equally effective against both oxacillin-susceptible and borderline oxacillin-resistant strains of S. aureus
- for strains in which the mechanism of resistance to S aureus is beta-lactamase production, piperacillin/tazobactam retains activity. There is no need to add a semisynthetic penicillin such as oxacillin
Rationale: Indications
- Most causes of cellulitis are caused by streptococci and S. aureus, so that beta-lactam antibiotics with activity against penicillinase-producing S. aureus are the typical antibiotics of choice for uncomplicated cellulitis in an immunocompetent host
- Ampicillin-sulbactam was highly effective in the prevention of experimental endocarditis caused by a beta-lactamase-producing, oxacillin-resistant coagulase-negative staphylococcal strain
Recommendations:
- based on current guidelines, there is no rationale nor indication for combination of Unasyn and Cloxacillin
- based on antibiotic spectrum and MIC, Unasyn will be able to cover for any other underlying S.Aureus infectionn
- https://www.drugs.com/pro/unasyn.html
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC187700/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC163064/
- http://www.antimicrobe.org/b237tabrev.htm#tab2
- Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.